Trial Profile

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Domatinostat (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab
Indications Malignant melanoma; Skin cancer
Focus Adverse reactions
Acronyms DONIMI

14 Nov 2023 Planned End Date changed from 1 Mar 2024 to 1 Nov 2024.
06 Jun 2023 Results of pooled analysis of OpACIN-neo, PRADO and DONIMI trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
13 Sep 2022 Results (Between Jan 2020-Oct 2021; At data cutoff Mar 18, 2022) assessing efficacy and safety of nivolumab and ipilimumab in stage III melanoma patients, presented at the 47th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com